Trials / Completed
CompletedNCT02753894
Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to examine the clinical dose range of ASP1585 based on the efficacy, safety, and feasibility of treatment in chronic kidney disease patients on hemodialysis with hyperphosphatemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP1585 | Oral |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2016-04-28
- Last updated
- 2016-06-21
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02753894. Inclusion in this directory is not an endorsement.